Lowell L. Hart, MD, FACP, discusses detection and treatment of interstitial lung disease for patients with HER2-positive breast cancer who received fam-trastuzumab deruxtecan-nxki.
Lowell L. Hart, MD, FACP
Advertisement
Articles by Lowell L. Hart, MD, FACP
Lowell L. Hart, MD, FACP, discusses the utility of antibody-drug conjugates in HER2-positive breast cancer.
Advertisement
Latest Updated Articles
Dr. Hart on Antibody-Drug Conjugates in HER2+ Breast CancerPublished: December 19th 2019 | Updated:
Dr. Hart on Detecting and Treating Interstitial Lung Disease in HER2+ Breast CancerPublished: January 14th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5